Long-term efficacy of botulinum toxin type A for the treatment of habitual dislocation of the temporomandibular joint

Br J Oral Maxillofac Surg. 2010 Jun;48(4):281-4. doi: 10.1016/j.bjoms.2009.07.014. Epub 2009 Aug 7.

Abstract

Injection of botulinum toxin type A (BTX-A) into the lateral pterygoid muscles is a recently reported treatment for habitual dislocation of the temporomandibular joint (TMJ). We report five cases of dislocation in elderly patients with neurological or other severe systemic disease, and their successful treatment with one injection of BTX-A into the lateral pterygoid muscles. This is a relatively conservative option. Injection into the muscle is straightforward and can be done in outpatients with few complications. We recommend it as the first choice for patients with habitual dislocation and systemic or neurological diseases, particularly in the elderly.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Botulinum Toxins, Type A / administration & dosage
  • Botulinum Toxins, Type A / therapeutic use*
  • Chronic Disease
  • Female
  • Follow-Up Studies
  • Humans
  • Imaging, Three-Dimensional
  • Injections, Intramuscular
  • Joint Dislocations / drug therapy*
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Neuromuscular Agents / administration & dosage
  • Neuromuscular Agents / therapeutic use*
  • Pterygoid Muscles / drug effects
  • Pterygoid Muscles / innervation
  • Recurrence
  • Temporomandibular Joint Disorders / drug therapy*
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A